Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease von Biegstraaten, M., Cox, T.M., Belmatoug, N., Berger, M.G., Collin-Histed, T., Vom Dahl, S., Di Rocco, M., Fraga, C., Giona, F., Giraldo, P., Hasanhodzic, M., Hughes, D.A., Iversen, P.O., Kiewiet, A.I., Lukina, E., Machaczka, M., Marinakis, T., Mengel, E., Pastores, G.M., Plöckinger, U., Rosenbaum, H., Serratrice, C., Symeonidis, A., Szer, J., Timmerman, J., Tylki-Szymańska, A., Weisz Hubshman, M., Zafeiriou, D.I., Zimran, A., Hollak, C.E.M.

Volltext

Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey von Deegan, P., Fernandez-Sasso, D., Giraldo, P., Lau, H., Panahloo, Z., Zimran, A.

Volltext

Prodromal substantia nigra sonography undermines suggested association between substrate accumulation and the risk for GBA‐related Parkinson's disease von Arkadir, D., Dinur, T., Becker Cohen, M., Revel‐Vilk, S., Tiomkin, M., Brüggemann, N., Cozma, C., Rolfs, A., Zimran, A.

Volltext

Sustained therapeutic effects of oral miglustat (Zavesca, N‐butyldeoxynojirimycin, OGT 918) in type I Gaucher disease von Elstein, D., Hollak, C., Aerts, J. M. F. G., Weely, S., Maas, M., Cox, T. M., Lachmann, R. H., Hrebicek, M., Platt, F. M., Butters, T. D., Dwek, R. A., Zimran, A.

Volltext

Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: An analysis of 798 patients from the ICGG Gaucher Registry von Fairley, C, Zimran, A, Phillips, M, Cizmarik, M, Yee, J, Weinreb, N, Packman, S

Volltext

P1633: LOW SERUM BDNF LEVELS ARE ASSOCIATED WITH LOWER PLATELETS’ CD62P REACTIVITY AND INCREASED BLEEDING TENDENCY IN PATIENTS WITH GAUCHER DISEASE von Azoulay, D., Naamad, M., Frydman, D., Broide, E., Zimran, A., Stemer, G., Revel‐Vilk, S.

Volltext

Anthropometric adjustments are helpful in the interpretation of BMD and BMC Z-scores of pediatric patients with Prader-Willi syndrome von Hangartner, T. N., Short, D. F., Eldar-Geva, T., Hirsch, H. J., Tiomkin, M., Zimran, A., Gross-Tsur, V.

Volltext

Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease von Elstein, D., Cohn, G.M., Wang, N., Djordjevic, M., Brutaru, C., Zimran, A.

Volltext

Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease von GIVOL, N., GOLDSTEIN, G., PELEG, O., SHENKMAN, B., ZIMRAN, A., ELSTEIN, D., KENET, G.

Volltext

The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement von Cox, T. M., Aerts, J. M. F. G., Andria, G., Beck, M., Belmatoug, N., Bembi, B., Chertkoff, R., Vom Dahl, S., Elstein, D., Erikson, A., Giralt, M., Heitner, R., Hollak, C., Hrebicek, M., Lewis, S., Mehta, A., Pastores, G. M., Rolfs, A., Sa Miranda, M. C., Zimran, A.

Volltext

Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease von van Dussen, L., Zimran, A., Akkerman, E.M., Aerts, J.M.F.G., Petakov, M., Elstein, D., Rosenbaum, H., Aviezer, D., Brill-Almon, E., Chertkoff, R., Maas, M., Hollak, C.E.M.

Volltext

Mandibular and dental manifestations of Gaucher disease von Saranjam, HR, Sidransky, E, Levine, WZ, Zimran, A, Elstein, D

Volltext

Occurrence of Parkinson's syndrome in type I Gaucher disease von Neudorfer, O, Giladi, N, Elstein, D, Abrahamov, A, Turezkite, T, Aghai, E, Reches, A, Bembi, B, Zimran, A

Volltext

Attitudes of couples identified through screening as carriers of Gaucher disease type 1 von Zuckerman, S, Lahad, A, Zimran, A, Levy-Lahad, E, Sagi, M

Volltext

GBA1 -Associated Parkinson's Disease Is a Distinct Entity von Skrahin, Aliaksandr, Horowitz, Mia, Istaiti, Majdolen, Skrahina, Volha, Lukas, Jan, Yahalom, Gilad, Cohen, Mikhal E, Revel-Vilk, Shoshana, Goker-Alpan, Ozlem, Becker-Cohen, Michal, Hassin-Baer, Sharon, Svenningsson, Per, Rolfs, Arndt, Zimran, Ari

Volltext

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy von Platt, F. M., Jeyakumar, M., Andersson, U., Priestman, D. A., Dwek, R. A., Butters, T. D., Cox, T. M., Lachmann, R. H., Hollak, C., Aerts, J. M. F. G., Van Weely, S., Hrebícek, M., Moyses, C., Gow, I., Elstein, D., Zimran, A.

Volltext

23 Beneficial effects of miglustat on skeletal symptoms in type I Gaucher disease: A meta-analysis von Pastores, Greg, Elstein, D., Hrebı´cek, M., Zimran, A.

Volltext

Neurocognitive testing in late-onset Tay–Sachs disease: A pilot study von Elstein, D., Doniger, G. M., Simon, E., Korn-Lubetzki, I., Navon, R., Zimran, A.

Volltext

Replacement therapy with imiglucerase for type 1 Gaucher's disease von Zimran, A., Elstein, D., Levy-Lahad, E., Zevin, S., Hadas-Halpern, I., Abrahamov, A., Bar-Ziv, Y., Schwartz, A., Foldes, J.

Volltext

Response to Torralba and Pérez-Calbo von Fairley, C., Zimran, A., Phillips, M., Cizmarik, M., Yee, J., Weinreb, N., Packman, S.

Volltext